Skip to content

The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension

The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension - The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027871
Enrollment
9
Registered
2017-06-22
Start date
2017-06-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

portal hypertension

Interventions

1.Insert the basket snare catheter into the hepatic vein from internal jugular vein. 2.Puncture the portal vein and insert the basket snare catheter into the portal vein. 3.Puncture the two basket s
gun sight&quot
method. 4.Insert the guidewire from the needle into the portal vein. 5.Catch the guidewire with the snare catheter and pull the guidewire out of the body. 6.Retrieve the needle and catch the same g

Sponsors

Osaka general medical center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.The patient with the refractory ascites or pleural effusion or gastrointestinal hemorrhage with portal hypertension. 2.Patients without thrombus in the intended hepatic vein or portal vein. 3.Patients without malignant tumor on the puncture line. 4. 1)white blood count:>=2000/mm3 2)platelet:>=50000/mm3 3)total serum bilirubin:<=3.0mg/dl 5.The MELD-Na score <= 17

Exclusion criteria

Exclusion criteria: 1.Patients with unpuncturable organ on the puncture line on images. 2.Patients with obvious tendency of bleeding or coagulation disorder. 3.Patients with antiplatelet, thrombolysis or anticoagulation therapy. 4.Patients who are judged inappropriate by the principal investigator.

Design outcomes

Primary

MeasureTime frame
severe or unexpected adverse events within 4 weeks

Countries

Japan

Contacts

Public ContactEiji Sugihara

Osaka general medical center Division of diagnostic imaging

eiji.sja2@gmail.com06-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026